Rona, Therapeutics Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia 07.08.2025 - 18:05:27 | prnewswire.co.uk Rona Therapeutics China New York View original content:https://www.prnewswire.co.uk/news-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia-302402731.html en | boerse | 67970457 |
